Abstract
Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Current Topics in Medicinal Chemistry
Title: Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Volume: 11 Issue: 5
Author(s): Alison C. Badrick and Christopher E. Jones
Affiliation:
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Abstract: Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Export Options
About this article
Cite this article as:
C. Badrick Alison and E. Jones Christopher, Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease, Current Topics in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/156802611794785181
DOI https://dx.doi.org/10.2174/156802611794785181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PET Measurements of cAMP-Mediated Phosphodiesterase-4 with (R)-[11C]Rolipram
Current Radiopharmaceuticals Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Current Pharmaceutical Design The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Role of Free Radicals and Antioxidant Signaling in Skeletal Muscle Health and Pathology
Infectious Disorders - Drug Targets Glycosaminoglycans, Protein Aggregation and Neurodegeneration
Current Protein & Peptide Science One-Pot Multi-Component Route to Propargylamines Using Zinc Oxide Under Solvent-Free Conditions
Combinatorial Chemistry & High Throughput Screening Frailty Among Alzheimer’s Disease Patients
CNS & Neurological Disorders - Drug Targets Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia
Current Pharmaceutical Design On the Design of Broad Based Screening Assays to Identify Potential Pharmacological Chaperones of Protein Misfolding Diseases
Current Topics in Medicinal Chemistry Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Novel Approaches for Potential Therapy of Cystic Fibrosis
Current Drug Targets Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
Current Medicinal Chemistry - Central Nervous System Agents Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)